Neopterin,Soluble IL-2 Receptor and IL-6 Secretion during IL-2 Cancer Immunotherapy: Prognostic Significance in Relation to IL-12 Variations

Abstract

Get full access to this article

View all access options for this article.

References

Whittington

, Faulds

Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Drugs 1993; 46: 446–514.

Huber

, Batchelor

J.R.

, Fuchs

. Immune response-associated production of neopterin: release from macrophages primarily under control of interferon-gamma. J Exp Med 1984; 160: 310–6.

Rubin

L.A.

, Kurman

C.C.

, Fritz

M.E.

. Soluble interleukin-2 receptors are released by activated lymphocytes in vitro. J Immunol 1985; 135: 3172–7.

Lissoni

, Pittalis

, Brivio

. In vitro modulatory effects of interleukin-3 on macrophage activation induced by interleukin-2. Cancer 1993; 71: 2076–81.

Lissoni

, Rovelli

, Tisi

. Relation between macrophage and T helper-2 lymphocyte functions in human neoplasms: neopterin, interleukin-10 and interleukin-6 blood levels in early or advanced solid tumors. J Biol Regul Homeost Agents 1995; 9: 146–9.

Banks

R.E.

, Patel

P.M.

, Selby

P.J.

Interleukin-12: a new clinical player in cytokine therapy.

Br J Cancer 1995; 71: 655–9.

Lissoni

, Fumagalli

, Barni

. Prognostic significance of changes in IL-12 secretion during cancer immunotherapy with IL-2: preliminary considerations. Int J Immunother, in press.